vTv Therapeutics appoints Dr. Keith Harris and Dr. Fahed Al Marzooqi to board

vTv Therapeutics Inc.

Dr. Keith Harris appointed as Board member and chair of Audit Committee; Dr. Fahed Al Marzooqi appointed as Board member.
Dr. Harris is a London-based investment banker with 30-year career at Morgan Grenfell, Drexel Burnham, Apax, and HSBC.
Dr. Al Marzooqi is COO of G42 Healthcare; his appointment follows the May 2022 stock purchase agreement with G42 Investments.
Each new director receives $35k annual cash, 25,000 options upon appointment, plus 25,000 options in annual equity grants.
Dr. Harris qualifies as independent and as an audit committee financial expert under SEC rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Keith Harris

member of the Board and a member and chair of the Audit Committee of the Board

VTVT · vTv Therapeutics Inc.

Effective: 2022-07-11
Filed: July 15, 2022, 7:59 PM ET

appointed (i) Dr. Keith Harris as a member of the Board and a member and chair of the Audit Committee of the Board, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Keith Harris was appointed as member of the Board and a member and chair of the Audit Committee of the Board at vTv Therapeutics Inc..

Action: appointed
Role: member of the Board and a member and chair of the Audit Committee of the Board

Exact text from the filing

appointed (i) Dr. Keith Harris as a member of the Board and a member and chair of the Audit Committee of the Board, effective immediately

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-002215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.